Vinblastine-Lance, lyophilizate 5 mg

Vinblastine is an alkaloid isolated from the plant of the genus Vinca (periwinkle).

Blocks mitotic cell division in the metaphase of the cell cycle.

It acts by binding to microtubules through inhibition of mitotic spindle formation.

In tumor cells it selectively inhibits synthesis of DNA and RNA through inhibition of DNA-dependent RNA polymerase.

In tumor cells.

Indications

Active ingredient

Composition

1 vial contains:

The active ingredient:

vinblastine sulfate in terms of 100% substance 5mg

Associates:

no

How to take, the dosage

It is set individually, depending on the indication and stage of the disease, the state of the hematopoiesis system, the scheme of anti-tumor therapy.

Interaction

Concomitant use with inhibitors of CYP3A isoenzyme activity may lead to an earlier appearance and/or worsening of the severity of vinblastine side effects.

Concomitant use with vinblastine may decrease the plasma concentration of phenytoin and decrease its anticonvulsant activity, presumably due to decreased absorption, increased metabolic rate and elimination of phenytoin.

The concomitant use of vinblastine in high doses with interferon alpha-n1 may cause severe myelodepression.

Special Instructions

With caution use vinblastine in patients with varicella (including recent or after contact with the disease), herpes zoster, other acute infectious diseases, gout, nephrolithiasis (including anamnesis). Patients with impaired liver function have an increased risk of toxic effects of vinblastine.

With caution, use with treatment with drugs that inhibit CYP3A isoenzyme activity.

The maximum depression of hematopoiesis (primarily a decrease in peripheral blood leukocyte counts) is achieved 5-10 days after discontinuation of vinblastine. Normalization of leukocyte count in peripheral blood is observed after 7-14 days. Development of thrombocytopenia (less than 200,000/μL) is most likely in patients who received prior antitumor or radiation therapy. Normalization of platelet counts is usually seen a few days after vinblastine withdrawal.

The risk of leukopenia with vinblastine is increased in patients with cachexia and ulcerative skin lesions, so it is not recommended for patients with the above conditions. In patients with bone marrow metastases, a marked decrease in leukocyte and platelet counts was observed after the use of vinblastine at medium doses. In these cases, further use of vinblastine is not indicated.

Liver transaminase activity and LDH, bilirubin level and plasma uric acid concentration should be monitored during therapy.

Vaccination of patients and their families is not recommended during treatment.

Vinblastine intrathecal administration may be fatal. Severe inflammation can occur if accidentally injected into the eyes.

Contraindications

Side effects

CNS and peripheral nervous system disorders: neuropathy, peripheral neuritis, headache, depression, seizures.

Hematopoietic system disorders: leukopenia, granulocytopenia, thrombocytopenia, anemia.

Digestive system disorders: anorexia, nausea, vomiting, abdominal pain, paralytic bowel obstruction, constipation, diarrhea, ulcerative stomatitis, hemorrhagic enterocolitis.

Cardiovascular system disorders: increase of BP, development of myocardial infarction, cerebral circulation disorders, increase of Raynaud’s disease symptoms.

Respiratory system: acute respiratory failure, bronchospasm.

Reproductive system disorders: azoospermia, amenorrhea.

Others: alopecia, bone pain.

Pregnancy use

Vinblastine is contraindicated in pregnancy. Breast-feeding should be discontinued if use is necessary during lactation.

When used in women of childbearing age, reliable contraceptive methods are recommended.

The teratogenic effect of vinblastine has been established in experimental studies.